ET-STEM ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 127 | Frontotemporal lobar degeneration | 1 |
127. Frontotemporal lobar degeneration
Clinical trials : 90 / Drugs : 87 - (DrugBank : 30) / Drug target genes : 39 - Drug target pathways : 88
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05315661 (ClinicalTrials.gov) | July 6, 2022 | 1/3/2022 | The Safety and The Efficacy Evaluation of ET-STEM in Patients With Frontotemporal Dementia | Clinical Assessment on the Safety and Potential Efficacy of Mesenchymal Stem Cells Preconditioned With Ethionamide (ET-STEM) in Patients With Frontotemporal Dementia (FTD) | Frontotemporal Dementia | Drug: ET-STEM | Samsung Medical Center | NULL | Recruiting | 40 Years | 85 Years | All | 12 | Phase 1 | Korea, Republic of |